Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

NCT06592768 is registered in ClinicalTrials.gov with Jasper Therapeutics, Inc. as lead sponsor.

NCT NCT06592768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06592768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Lead sponsor
Jasper Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 26, 2024
Completion date
August 11, 2025
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma